The objectives of this study were 1) to determine how cellular growth of skeletal muscle is altered by the repartitioning agent cimaterol and 2) to determine if cimaterol alters endocrine status in association with its repartitioning effects. Thirty Dorset wether lambs were randomly assigned to a pre-treatment baseline group or received 0 or 10 ppm cimaterol in a complete, mixed, high-concentrate diet for 7 or 12 wk. Weights of biceps femoris (BF), semimembranosus (SM) and semitendinosus (ST) muscles were 32.8, 27.1 and 31.5% greater, respectively, in treated lambs at 7 wk, and were 22 to 24% greater at 12 wk. Longissimus (LD) cross-sectional area was 26 and 32% greater at these treatment intervals. Percent type I fibers declined significantly over the course of the experiment in ST, SM and LD, and cimaterol caused a small but significant reduction in percent type I fibers in the ST at 7 and 12 wk. Muscles from lambs fed cimaterol contained 50 and 75% more fibers that exhibited negative staining for phosphorylase activity. Mean cross-sectional area of type I and type II fibers in the combined portions of the ST were 30.4 and 29.3% greater, respectively, in cimaterol-fed lambs after 12 wk, while type I and type II fiber areas in the longissimus were only 13 and 15% greater, respectively. Cimaterol-induced hypertrophy of the ST resulted in both protein and RNA content being 30 to 35% greater (P less than .01) at 7 and 12 wk, while DNA concentration was 22% less (P less than .01) at 7 wk. DNA concentration returned to normal by 12 wk. These results indicate that cimaterol elicits a rapid increase in muscle RNA and protein accretion without concurrent incorporation of satellite cell nuclei. Plasma insulin and insulin-like growth factor-1 (IGF-1) concentrations were 55 and 34% lower, respectively, in cimaterol-fed lambs. Plasma somatotropin concentration and area under the curve were 2.3 times greater (P less than .01) in lambs fed cimaterol for 6 wk, while plasma cortisol, prolactin and glucose concentration were unaffected at 6 or 12 wk. The significant changes in endocrine status may be important in the mechanism(s) of cimaterol in altering muscle accretion.
Ten crossbred (Suffolk X Rambouillet) whether lambs were randomly assigned to receive 0 or 10 ppm cimaterol (CIM) in a completely mixed high-concentrate diet for 8 wk. Total weight gain and feed efficiency were improved 29% (P less than .05) and 14%, respectively, in the CIM-fed group. CIM also improved (P less than .01) dressing percent by 4.9 percentage points and improved yield grade by one grade. CIM increased longissimus muscle (LD) area 38% (P less than .01) and the yield of four lean cuts 28% (P less than .01). No difference was found in the proportion of type I (slow-contracting, oxidative) and type II (fast-contracting, mixed glycolytic/oxidative) fibers in LD and semitendinosus (ST) muscles between control and CIM groups, indicating no change in fiber type. The cross-sectional area of type II fibers in LD and ST muscles of the CIM group was 2,081 and 1,951 micron 2 as compared with 1,391 and 1,296 micron2 of the control group, respectively. The increase was approximately 50% (P less than .01). No difference was found in cross-sectional area of type I fibers, indicating that the increase of muscle mass was due to hypertrophy of type II fibers only. DNA concentration (micrograms/g wet muscle or microgram/g protein) of CIM muscle was much lower (P less than .01) than that of control muscle, suggesting that the protein accretion in muscle was accomplished without additional incorporation of nuclei from satellite cells.
An enzymatic glycogen determination is used for bovine and poircine skeletal muscle. Perchloric acid homogenates of muscle are sampled, and mixed with amyloglucosidase which extracts the glycogen and reduces it to glucose. The glucose is then analysed with specific enzymes. The use of perchloric acid homogenates allows the determination of metabolites in the protein free extract of the same homogenate. Compared with the KOH-ethanol glycogen extraction method the amyloglucosidase method indicated higher levels of glycogen which were attributed to protein-bound glycogen and ethanol soluble carbohydrate not determined by the KOH-ethanol method.
A randomized complete-block design was used to evaluate the effects of the beta-adrenergic agonist, cimaterol (CL 263,780), on growth rate, feed efficiency and carcass composition of finishing swine. The drug was fed at four levels (0, .25, .5 and 1.0 ppm) to a total of 240 pigs from 64.5 to 103.7 kg live weight. Growth rate and feed efficiency were measured during the 7-wk feeding trial. Feeding cimaterol depressed feed intake, improved feed efficiency and did not alter rate of gain. Carcass evaluation showed that pigs continuously fed cimaterol had 13.2, 9.3 and 9.2% less fat measured at the 10th rib, P2 and average backfat (BF) locations, respectively, compared with controls. Cimaterol-fed pigs had increased loin eye areas (10.9%), and increased semitendinosus (11.8%) and biceps femoris (8.9%) weights compared with controls. The semitendinosus muscles of the cimaterol-fed pigs had less fat and the femur bones were shorter and lighter weight than controls. There were no detected differences in structural soundness of the live pigs, but postmortem evaluation of the hooves indicated that pigs fed 1.0 ppm cimaterol had a higher incidence of hoof lesions. Pigs withdrawn from cimaterol for 7 d were comparable in performance and carcass characteristics with those continuously fed the drug except that carcass fat measurements had generally returned to control values. The data indicate that cimaterol improved the feed efficiency of finishing pigs and increased the lean:fat ratio of their carcasses. Withdrawal of cimaterol caused compensatory fat deposition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.